Suppr超能文献

作为 ABL 抑制剂的没食子酸衍生物的分子静电势、对接和动力学模拟的计算研究。

Computational study of molecular electrostatic potential, docking and dynamics simulations of gallic acid derivatives as ABL inhibitors.

机构信息

School of Chemical Sciences, Kannur University, Edat, Kannur, 670327, Kerala, India; Indian Institute of Information Technology and Management-Kerala, Trivandrum, 695581, Kerala, India.

Indian Institute of Information Technology and Management-Kerala, Trivandrum, 695581, Kerala, India.

出版信息

Comput Biol Chem. 2018 Jun;74:239-246. doi: 10.1016/j.compbiolchem.2018.04.001. Epub 2018 Apr 5.

Abstract

Chronic myeloid leukemia (CML), a hematological malignancy arises due to the spontaneous fusion of the BCR and ABL gene, resulting in a constitutively active tyrosine kinase (BCR-ABL). Pharmacological activity of Gallic acid and 1,3,4-Oxadiazole as potential inhibitors of ABL kinase has already been reported. Objective of this study is to evaluate the ABL kinase inhibitory activity of derivatives of Gallic acid fused with 1,3,4-Oxadiazole moieties. Attempts have been made to identify the key structural features responsible for drug likeness of the Gallic acid and the 1,3,4-Oxadiazole ring using molecular electrostatic potential maps (MESP). To investigate the inhibitory activity of Gallic acid derivatives towards the ABL receptor, we have applied molecular docking and molecular dynamics (MD) simulation approaches. A comparative study was performed using Bosutinib as the standard which is an approved CML drug acting on the same receptor. Furthermore, the novel compounds designed and reported here in were evaluated for ADME properties and the results indicate that they show acceptable pharmacokinetic properties. Accordingly these compounds are predicted to be drug like with low toxicity potential.

摘要

慢性髓性白血病(CML)是一种血液系统恶性肿瘤,由于 BCR 和 ABL 基因的自发融合而产生,导致组成性激活的酪氨酸激酶(BCR-ABL)。已经报道了没食子酸和 1,3,4-恶二唑作为潜在的 ABL 激酶抑制剂的药理学活性。本研究的目的是评估与 1,3,4-恶二唑部分融合的没食子酸衍生物的 ABL 激酶抑制活性。已经使用分子静电势图(MESP)尝试确定负责没食子酸和 1,3,4-恶二唑环药物相似性的关键结构特征。为了研究没食子酸衍生物对 ABL 受体的抑制活性,我们应用了分子对接和分子动力学(MD)模拟方法。使用博舒替尼作为标准进行了比较研究,博舒替尼是一种作用于相同受体的已批准的 CML 药物。此外,还对这里设计和报道的新型化合物进行了 ADME 性质评估,结果表明它们具有可接受的药代动力学性质。因此,这些化合物具有较低毒性潜力,预计具有类药性。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验